September 29, 2005. In a Phase III trial, milnacipran, a novel drug that showed a great deal of promise in earlier tests, failed to confer a statistically significant benefit on patients suffering from fibromyalgia. Forest Labs and Cypress Bioscience, the joint developers, have pledged to continue work on the compound. The news put a sizeable dent in the stock price of both companies. We look at the mechanism and history of the drug...
